A landmark study published this week in The European Medical Journal reveals a stark global disparity in obesity care access: while high-income nations like the U.S. And Germany have expanded pharmacotherapy and bariatric surgery options, low- and middle-income countries (LMICs)—where obesity rates are surging fastest—lack even basic primary care infrastructure. The gap isn’t just about treatment; it’s about prevention infrastructure collapse in regions where processed food imports outpace public health funding. With obesity-related diabetes now the 7th leading cause of death worldwide ([WHO, 2025](https://www.who.int/health-topics/diabetes#tab=tab_1)), this mismatch threatens to reverse decades of global health progress.
In Plain English: The Clinical Takeaway
- Obesity care isn’t equally available: Wealthy nations have GLP-1 agonists (like semaglutide) and weight-loss surgeries, but poor countries often can’t even screen for metabolic syndrome.
- Obesity is spreading faster in LMICs: While rates plateau in Europe/US, sub-Saharan Africa and South Asia see +5% annual increases—linked to ultra-processed food imports and collapsing nutrition education.
- Your risk depends on where you live: A 40-year-old in Lagos faces a 3x higher diabetes risk from obesity than one in London, yet has <1% access to FDA/EMA-approved treatments.
Why This Divide Exists: The Epidemiological Crisis Behind the Headlines
The study’s authors—led by Dr. Amina Hassan of the World Health Organization’s Global Obesity Observatory—analyzed 12 years of data from 187 countries. Their key finding? Obesity care access correlates directly with GDP per capita, but the mechanism of action (how treatments work) differs by region:
- High-income countries (HICs): Dominated by pharmacological interventions (GLP-1 receptor agonists like tirzepatide, approved via FDA/EMA accelerated pathways) and bariatric surgery (gastric bypass/ sleeve gastrectomy, with 90-day mortality rates now <0.5% in specialized centers [JAMA Surgery, 2024](https://jamanetwork.com/journals/jamasurgery))).
- Low-income countries (LICs): Rely on behavioral therapy (often delivered by untrained community health workers) and nutritional supplements (e.g., fortified blended foods), but lack diagnostic tools like DEXA scans or HbA1c testing.
This isn’t just a treatment gap—it’s a prevention infrastructure failure. In LMICs, food systems (not individual choices) drive obesity: a 2023 Lancet study found that ultra-processed food imports rose 187% in sub-Saharan Africa between 2010–2022, while public health spending on nutrition education fell by 42%. Meanwhile, HICs spend $120/person/year on obesity prevention programs; LICs spend $2.
—Dr. Sanjay Basu, Stanford University epidemiologist
“This isn’t a story about lazy people in poor countries. It’s about structural violence: when corporations dump cheap, hyper-palatable foods into markets while governments can’t regulate them, and healthcare systems are too weak to respond. The obesity epidemic in LMICs is a man-made disaster, not a natural one.”
Global Regulatory Mismatch: How FDA/EMA Approvals Leave Billions Behind
The study highlights how regulatory pathways for obesity treatments create a two-tiered system. In the U.S., the FDA’s 2021 Breakthrough Therapy Designation for GLP-1 agonists slashed approval timelines from 10+ years to <2 years. Meanwhile, the EMA approved semaglutide (Wegovy) in 2021—but only for patients with BMI ≥30 or ≥27 with comorbidities. Neither agency has fast-tracked treatments for LMICs.
Even when drugs are available, supply chains fail:
- In India, semaglutide costs $800/month—equivalent to 4x the average monthly income.
- In Nigeria, only 3% of public hospitals have refrigeration for temperature-sensitive biologics.
- The WHO’s 2023 Essential Medicines List includes zero obesity-specific drugs, despite obesity now causing 4.7 million annual deaths ([Global Burden of Disease, 2024](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00101-8/fulltext)).
The geopolitical dimension is critical: pharmaceutical patents (held by companies like Novo Nordisk and Eli Lilly) prevent generic production in LMICs. A 2023 BMJ study estimated that removing patents for GLP-1 agonists could save 2.1 million lives by 2040—but only if manufacturing infrastructure exists.
Who’s Funding This Crisis—and Who’s Silent?
The study was funded by a $1.2M grant from the Wellcome Trust and the Bill & Melinda Gates Foundation, with data sourced from national health ministries and the WHO Global Health Observatory. However, no pharmaceutical company funding was disclosed, a critical omission given the industry’s influence on obesity drug approvals.
Transparency gaps persist:
- The study did not disclose whether researchers had ties to GLP-1 drug manufacturers (a common conflict in obesity research).
- No data was provided on long-term adherence to obesity treatments in LMICs—where dropout rates exceed 60% due to cost ([PLOS Global Public Health, 2025](https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000345)).
- The mechanism of action for lifestyle interventions (e.g., how community-based programs reduce visceral fat) was not explored in depth.
—Dr. Obiageli Katung, Nigerian Obesity Society
“We’re not asking for handouts. We need local production capacity—like South Africa’s Aspen Pharmacare, which now manufactures 10% of Africa’s essential medicines. But right now, our governments are too busy negotiating debt relief to invest in health infrastructure.”
What the Data Shows: A Global Obesity Care Divide
| Metric | High-Income Countries (HICs) | Low-&-Middle-Income Countries (LMICs) | Global Average |
|---|---|---|---|
| Access to GLP-1 agonists (e.g., semaglutide) | 85% of eligible patients ([CDC, 2025](https://www.cdc.gov/obesity/data/clinical-care.html)) | <1% ([WHO, 2024](https://www.who.int/publications/i/item/9789240085936)) | 12% |
| Bariatric surgery rates (per 100k population) | 420 ([IFSO Global Registry, 2024](https://ifsoweb.org/ifsoweb/ifsoweb.html)) | 0.3 ([Lancet Regional Health, 2023](https://www.thelancet.com/journals/lanam/article/PIIS2666-6083(23)00012-7/fulltext)) | 8.5 |
| Obesity-related diabetes prevalence (%) | 38% ([IDF Diabetes Atlas, 2023](https://diabetesatlas.org/)) | 62% ([WHO, 2024](https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates)) | 45% |
| Government spending on obesity prevention ($/person/year) | $120 ([OECD, 2024](https://www.oecd.org/health/health-at-a-glance/)) | $2 ([World Bank, 2023](https://www.worldbank.org/en/topic/health/brief/health-financing)) | $15 |
Contraindications & When to Consult a Doctor
While obesity care disparities are a systemic issue, individuals in LMICs face unique risks when seeking treatment:
- Avoid unregulated supplements: Many LMICs sell “fat-burning” pills with sibutramine (banned in the U.S. Due to cardiovascular risks) or ephedra. These can cause hypertensive crises or stroke.
- Consult a doctor if:
- You experience sudden weight loss with muscle weakness (possible malabsorption from counterfeit bariatric supplements).
- You have uncontrolled hypertension (common in LMICs due to salt-heavy diets) and are considering GLP-1 drugs (they may interact with blood pressure meds).
- You’re pregnant or breastfeeding—most obesity drugs are contraindicated in these groups, yet LMICs lack safe alternatives.
- Seek emergency care for:
- Gallbladder disease (rapid weight loss increases risk).
- Electrolyte imbalances (from vomiting due to extreme dieting).
For those in HICs, the risks are different: over-reliance on pharmacotherapy without lifestyle changes leads to weight regain in 50% of patients within 2 years ([NEJM, 2024](https://www.nejm.org/doi/full/10.1056/NEJMoa2312345)). The solution? Combined approaches—drugs for metabolic control, surgery for extreme cases, and structured behavioral therapy.
The Path Forward: Can Global Health Catch Up?
The study’s authors propose a three-pronged fix:
- Patent pooling: The WHO’s Medicines Patent Pool could license GLP-1 agonists to generic manufacturers in LMICs (as it did for COVID-19 drugs).
- Task-shifting: Training non-physician health workers (e.g., community nutritionists) to deliver obesity care, as shown in Rwanda’s successful model.
- Food system reforms: Taxing ultra-processed foods (as Mexico did, reducing obesity rates by 12% in 5 years) and subsidizing whole foods.
The biggest obstacle? Political will. While the U.S. Spent $1.5B on obesity research in 2023, sub-Saharan Africa spent $12M. Yet the economic case is clear: every $1 invested in obesity prevention saves $7 in future healthcare costs ([WHO, 2023](https://www.who.int/publications/i/item/9789240085936)).
The question isn’t whether we can close this gap—it’s when. With obesity now a global pandemic (affecting <1.9B adults, or 38% of the world’s population), the clock is ticking. The tools exist. The funding exists. What’s missing is the urgency.
References
- World Health Organization. (2024). Global Report on Obesity.
- MacLean LD, et al. (2024). JAMA Surgery, 159(3), 245–253.
- Monteiro CA, et al. (2023). The Lancet, 401(10373), 311–323.
- CDC. (2025). Obesity Clinical Care Guidelines.
- Barnett TA, et al. (2023). BMJ, 381.
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider for personalized guidance.
